Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1

Interventions

blinatumomab 10Cyclophosphamide 6fludarabine 4Vincristine 4Methotrexate 4Dexamethasone 4Cytarabine 4venetoclax 3Whole-Body Irradiation 2Thiotepa 2Therapeutics 2Mercaptopurine 2Exercise 2Busulfan 2ruxolitinib 1revumenib 1ponatinib 1pegaspargase 1olverembatinib 1navitoclax 1fludarabine phosphate 1etoposide phosphate 1capivasertib 1asciminib 1Ultrasonography 1Transplantation 1Prednisolone 1Melphalan 1Levofloxacin 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Precursor Cell Lymphoblastic Leukemia-Lymphoma × BEBT-908 × Clear all
NCT07301138 2025-12-24

BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients

Ruijin Hospital

Phase 2 Not yet recruiting
23 enrolled
LymphoidOther hematologic neoplasm

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡